Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/8/2026, 12:00:00 AM
The sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab is expected to be accepted for review by China's NMPA; this regulatory progress is estimated to have a 5% price impact expected.
Korean Translation
비소세포폐암 치료를 위한 sac-TMT 병용 요법의 sNDA 심사 접수가 예상되며, 이는 주요 규제 마일스톤 달성으로 약 5%의 주가 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM